Related Experiment Video
Updated: Jul 17, 2026
MicroRNA Detection in Prostate Tumors by Quantitative Real-time PCR (qPCR)
Published on: May 16, 2012
Interleukin 6 receptor mRNA in prostate carcinomas and benign prostate hyperplasia
M J Siegsmund1, H Yamazaki, I Pastan
1Laboratory of Molecular Biology, DCBDC, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892.
Abstract:
We investigated the presence of interleukin 6 (IL6) receptors in human prostate carcinomas and benign prostatic hyperplasias. Interleukin 6 receptor expression was measured at the mRNA level by slot blot analysis using a probe that recognizes mRNA encoding the 80-kDa subunit of the IL6 receptor. Significant expression was found in 29 of 37 (78%) samples of benign prostate hyperplasia (BPH) and in 17 of 17 prostate carcinomas. Quantitative analysis of the expression level revealed that 11 of the 29 positive hyperplasia tissues (38%) and 4 carcinoma samples (23.5%) expressed equal or higher levels of IL6 receptor mRNA than the human hepatoma cell line PLC/PRF5, which contains about 2300 IL6 receptors per cell. We also measured IL6 receptor mRNA levels in three human prostate carcinoma cell lines LNCaP, DU145 and PC3, which are known to contain IL6 receptors because they are sensitive to the cytotoxic action of an IL6-toxin fusion protein. We were not able to detect IL6 receptor expression with the slot blot procedure, but we were able to detect IL6 receptor mRNA using a very sensitive PCR assay. Our data provide evidence that IL6 may play a role in the growth of benign and malignant prostate tumors and suggest that the IL6 receptor could be a target for the delivery of therapeutic agents in prostate cancer.
Insights
Interleukin 6 (IL6) receptors are present in most benign and malignant prostate tissues. This suggests the IL6 receptor could be a therapeutic target for prostate cancer treatment.
Area of Science:
- Oncology
- Molecular Biology
- Immunology
Background:
- Interleukin 6 (IL6) is a cytokine implicated in various cellular processes, including inflammation and cell growth.
- The role of IL6 and its receptor in prostate cancer development and progression is not fully understood.
Purpose of the Study:
- To investigate the expression of the interleukin 6 (IL6) receptor in human prostate benign hyperplasias and carcinomas.
- To determine if IL6 receptor expression correlates with prostate tumor growth and could serve as a therapeutic target.
Main Methods:
- Utilized slot blot analysis to measure interleukin 6 (IL6) receptor mRNA levels in prostate tissues.
- Employed a sensitive PCR assay to detect IL6 receptor mRNA in prostate cancer cell lines.
- Quantified IL6 receptor mRNA expression relative to a human hepatoma cell line (PLC/PRF5).
Main Results:
- Significant interleukin 6 (IL6) receptor mRNA expression was detected in 78% of benign prostatic hyperplasia (BPH) samples and 100% of prostate carcinomas.
- A subset of BPH and carcinoma tissues exhibited IL6 receptor mRNA levels comparable to or exceeding those of the PLC/PRF5 cell line.
- While slot blot analysis failed to detect IL6 receptor expression in prostate cancer cell lines, a sensitive PCR assay confirmed its presence.
Conclusions:
- Interleukin 6 (IL6) signaling likely contributes to the growth of both benign and malignant prostate tumors.
- The IL6 receptor represents a potential therapeutic target for drug delivery in prostate cancer treatment.
